Evidence map›Paper›PMID 15923516›Full record

ReviewThe British journal of ophthalmology2005

Spare the rod and spoil the eye.

G B Arden, R L Sidman, W Arap, R O Schlingemann

Open access · bronzeAbstract readReview
In one paragraph

Review in The British journal of ophthalmology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 146 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Effect of light and diurnal variation on macular thickness in X-linked retinoschisis: a case series.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020
    Article
  16. Article
  17. Article
  18. Review
  19. The flicker Pupil Light Response (fPLR).Translational vision science & technology · 2019
    Article
  20. Correlation of retinal vascular perfusion density with dark adaptation in diabetic retinopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

G B ArdenHenry Wellcome Laboratories, Applied Vision Research Centre, Department of Optometry and Visual Science, City University, Northampton Square, London EC1V 0HB, UK. g.arden@city.ac.uk
R L Sidman
W Arap
R O Schlingemann
City, University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review presents a new unified view of the pathogenesis of three common causes of acquired retinal degenerative disease-diabetic retinopathy, age related macular degeneration, and retinopathy of prematurity. In these three conditions, angiogenesis has a predominant role in the development of sight threatening pathology. Angiogenesis is controlled by among other factors the expression of vascular endothelial growth factor (VEGF), which in turn is regulated by absolute and relative lack of oxygen. The severe pathological manifestations of these three conditions are not part of a general underlying disease process because they are peculiar to the eye, and the profound hypoxia that develops in normal retina during dark adaptation (rod driven hypoxia) is an adequate and elegant additional factor to explain their pathogenesis. A large number of experimental reports support this conclusion, although rod driven anoxia is not generally considered as a causal factor in ocular disease. However, the hypothesis can be critically tested, and also suggests novel methods of treatment and prevention of these conditions that may be simpler and more inexpensive than current therapies and that have a smaller potential for adverse effects.

Indexed as

AnimalsCell HypoxiaCytokinesDark AdaptationDiabetic RetinopathyHumansInfant, NewbornMacular DegenerationRetinal DiseasesRetinal NeovascularizationRetinal Rod Photoreceptor CellsRetinopathy of PrematuritySignal TransductionVascular Endothelial Growth Factor ACytokinesVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID15923516
PMCPMC1772679
OpenAlexW2116590919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.